Shots:

• The NDA submission is based on P-III FINCH program- including FINCH 1- 2 & 3 study evaluating the safety & efficacy of Filgotinib (100/200mg- qd) in patients with RA ranging from early-stage to biologic-experienced patients
• The P-III FINCH program demonstrated improvement in signs and symptoms- to achieve low disease activity and remission and inhibits structural damage in patients with RA. Safety data is consistent with the previous results
• Filgotinib is an investigational- oral- selective JAK1 inhibitor being evaluated in P-II EQUATOR study for psoriatic arthritis- P-II TORTUGA study for ankylosing spondylitis- P-III DIVERSITY for Crohn’s disease and P-III SELECTION study for UC

Click here to­ read full press release/ article 

 Ref: Gilead | Image:Gilead